REMARKS

Applicant has amended claims 16 and 17 to recite methods that "consist of" particular steps. Support for these amendments are found on page 10, lines 12-15.

35 U.S.C. § 103(a) Rejections

Claims 1, 2, 5-7 and 10 stand rejected under 35 U.S.C. 103(a) for purportedly being unpatentable over Komer U.S. Patent No. 5,773,422 ("Komer") in view of Huet et al., U.S. Patent No. 6,482,425, ("Huet"). Applicant respectfully disagrees and in view of the following remarks request that the Examiner reconsider and withdraw the rejection.

The Examiner contends that Komer discloses a pharmaceutical composition comprising ivermectin, propylene glycol and poly sorbate 80 and benzyl alcohol but does not disclose the addition of ethanol or isopropanol. However, Applicant's claimed pharmaceutical solutions "consists essentially of" ivermectin, propylene glycol and poly sorbate 80 and benzyl alcohol and do not require N-methylpyrrolidone or 2-pyrrolidone. In contrast, each and every pharmaceutical solution disclosed by Komer also includes either N-methylpyrrolidone or 2-pyrrolodone as necessary components to dissolve the invermectin. As such, Komer fails to teach or suggest the claimed invention, which is limited to the claimed essential ingredients plus any compounds present

Reply Dated: April 19, 2007

in impurity level concentrations. Huet does not compensate for Komer's

deficiencies.

The Examiner contends that Huet teaches that benzyl alcohol, ethanol

and isopropanol can interchangeably be used in invermectin containing

compositions. But Huet fails to teach a pharmaceutical composition limited to

the claimed essential ingredients and as such one of skill in the art would have

no motivation to remove N-methylpyrrolidone from Komer's compositions. As

such, the combination of Komer and Huet fails to render the claimed invention

obvious.

Claims 10-12, 15 and 16 stand rejected under 35 U.S.C. 103(a) for

purportedly being unpatentable over Komer. Applicant respectfully disagrees

and in view of the following remarks requests that the Examiner reconsider and

withdraw the rejection of the claims.

Claim 10 depends on claim 6, which requires that the pharmaceutical

solution consists essentially of Ivermectin, 10-99% v/v isopropyl alcohol,

propylene glycol and polysorbate 80. Komer only teaches pharmaceutical

solutions using N-methylpyrrolidone or 2-pyrrolodone as a primary solvent to

dissolve Ivermectin. The Examiner cites Examples 14 and 17 as disclosing a

formulation comprising ivermectin, propylene glycol and polysorbate 80. The

Examiner acknowledges Komer does not disclose the amounts of propylene glycol

and polysorbate 80 encompassed by Applicant's claims, but contends a person of

Page 7 of 12

ordinary skill in the art would have been motivated to add additional amounts of propylene glycol and polysorbate 80 to the composition without adversely However, Applicant's claimed pharmaceutical affecting the composition. solutions consist essentially of particular components and do not require Nmethylpyrrolidone or 2-pyrrolidone. In contrast, each and every pharmaceutical solution disclosed by Komer also includes either N-methylpyrrolidone or 2pyrrolidone as necessary components to dissolve the invermectin. Furthermore, Applicant's claimed pharmaceutical compositions comprise 10-99% isopropyl alcohol, in addition to propylene glycol and polysorbate 80. Komer's Examples 14 and 17 and Col. 3, lines 6-45 do not disclose isopropyl alcohol. As such, Komer fails to teach or suggest Applicant's claimed invention, which consists essentially of ivermectin, 10-99% v/v isopropyl alcohol, propylene glycol and polysorbate 80 plus any compounds present in impurity level concentrations. Accordingly, Applicant respectfully requests that the Examiner withdraw the rejection of claims 10-12, 15 and 16 under 35 U.S.C. 103 based on Komer.

Regarding claims 11, 12, and 15, as discussed above, each and every pharmaceutical solution disclosed by Komer also includes either N-methylpyrrolidone or 2-pyrrolidone as necessary components to dissolve the invermectin. Applicant's claimed pharmaceutical solution consists essentially of particular components and does not require N-methylpyrrolidone or 2-pyrrolidone. As such, Komer fails to teach or suggest the claimed invention and

Applicant respectfully requests that the Examiner reconsider and withdraw the

rejection of claims 11, 12 and 15 under 35 U.S.C. 103 in view of Komer.

Regarding the rejection of claim 16, as discussed above, each and every

formulation disclosed by Komer was prepared using either N-methylpyrrolidone

2-pyrrolidone as necessary components to dissolve the invermectin.

Applicant's method as claimed consists of particular steps that do not include

using either N-methylpyrrolidone or 2-pyrrolidone as necessary components to

dissolve the invermectin and Komer does not suggest excluding the step of

dissolving ivermectin in N-methylpyrrolidone or 2-pyrrolidone from the method.

As such Komer does not render Applicant's invention obvious and Applicant

respectfully requests that the Examiner reconsider and withdraw the rejection of

claim 16 under 35 U.S.C. 103 in view of Komer.

Claims 17, 18, 22 and 23 stand rejected under 35 U.S.C. 103(a) for

purportedly being unpatentable over Komer in view of Lacy et al. U.S. Patent

No. 5,645,856 ("Lacy"). Applicant respectfully disagrees and in view of the

following remarks and amendments to the claims requests that the Examiner

reconsider and withdraw the rejection of the claims.

As discussed above, each and every pharmaceutical solution disclosed by

Komer was prepared using either N-methylpyrrolidone or 2-pyrrolidone as

necessary components to dissolve the invermectin. Applicant's methods as

claimed consist of particular steps that do not include using either N-

Page 9 of 12

methylpyrrolidone or 2-pyrrolidone to dissolve the invermectin and Komer does not suggest excluding N-methylpyrrolidone or 2-pyrrolidone from the method. Lacy does not compensate for Komer's deficiencies. Lacy merely provides a list of sweeteners (Col. 14, lines 2-3). As such Komer alone or in combination with Lacy does not render Applicant's invention obvious. Applicant respectfully requests that the Examiner reconsider and withdraw the rejection of claim 16 under 35

Claims 19-21 stand rejected under 35 U.S.C. 102(b) for purportedly being anticipated by, or in the alternative, under 35 U.S.C. 103(a) for purportedly being obvious over Komer.

U.S.C. 103(a) over Komer in view of Lacv.

The Examiner contends that if there are differences in amounts of the components present in the Komer formulations and the claimed compositions, such difference would appear minor in nature and the claimed compositions would be prima facie obvious from Komer's disclosure. Applicant respectfully disagrees.

The Examiner acknowledges that the claims are limited to the terminology "consisting essentially of" but contends that Applicant failed to show that N-methylpyrrolidone present in the formulation of Example 14 and 17 would materially affect the basic and novel characteristics of the claimed invention (Office Action page 4). However, Komer's statements of the unexpected solubility of avermectins in N-methylpyrrolidone and the advantages of including N-methylpyrrolidone in his invermectin formulations (Col. 2, lines

47-61) demonstrate that one of skill in the art believes that N-methylpyrrolidone

materially affects the basic and novel characteristics of those formulations.

Therefore, one skilled in the art would also expect N-methylpyrrolidone to affect

the basic and novel characteristics of the claimed invention. As such, the term

"consisting essentially of" excludes N-methylpyrrolidone from the claimed

invention.

Komer does not teach or suggest pharmaceutical compositions consisting

essentially of ivermectin, propylene glycol and polysorbate 80 and therefore does

not anticipate or render the claimed invention obvious. In view of the foregoing

remarks, Applicant respectfully requests that the Examiner reconsider and

withdraw the rejection of claims 19-21 under 35 U.S.C. 102(b), or in the

alternative, under 35 U.S.C. 103(a) for purportedly being anticipated by, or

obvious over, Komer.

CONCLUSION

Applicant believes the present paper to be a complete and thorough

response to the Non-Final Office Action. In view of the foregoing amendments

and remarks, the application is respectfully submitted to be in condition for

allowance. Accordingly, a timely favorable action is earnestly solicited.

Page 11 of 12

Application No. 10/806,683 Reply Dated: April 19, 2007

If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket #101918.56959C1).

Respectfully submitted,

April 19, 2007

John W. Ryan

Registration No. 33,771

Mary Anne Schofield Registration No. 36,669

CROWELL & MORING LLP Intellectual Property Group P.O. Box 14300 Washington, DC 20044-4300 Telephone No.: (202) 624-2500 Facsimile No.: (202) 628-8844

MAS:mas 2964932v1